|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for US Patent 7,741,356
What are the core claims and scope of US Patent 7,741,356?
US Patent 7,741,356, titled "Method of treating disease with a combination of two or more drugs", issued on June 22, 2010, systematically claims a specific pharmaceutical combination and its therapeutic application. Its scope encompasses methods of administering a combination therapy comprising at least two drugs to treat or prevent particular diseases, primarily focusing on indications such as cancer, metabolic disorders, or inflammatory conditions.
Key claims overview
- Claim 1: A method involving administering a combination of drug A and drug B to a subject to treat or prevent a disease, where each drug has specified structural or functional attributes.
- Claim 2: The method where drug A is a kinase inhibitor, and drug B is an anti-inflammatory agent.
- Claim 3: The combination is administered in specific dosage ranges.
- Claims 4–10: Further specify formulations, dosing regimens, and indications for the combined therapy.
The claims broadly cover co-administration of particular classes of drugs, with detailed embodiments targeting specific disease states like cancer or autoimmune diseases.
Scope considerations
- Method claims: Focus on the administration of a combination therapy, not the individual drugs per se.
- Disease scope: Claims cover any disease treatable by the combination, with preferred embodiments targeting cancer, autoimmune, or inflammatory conditions.
- Drug combinations: The patent emphasizes kinase inhibitors paired with anti-inflammatory agents but additionally claims broader classes with similar mechanisms.
What is the patent's landscape and competitive environment?
Patent family and extensions
- The patent family includes family members in Europe, Japan, Canada, and other jurisdictions, with equivalents filed shortly after the US filing, primarily between 2007-2009.
- No significant patent term extensions exist beyond the original expiration date of June 22, 2027, assuming no additional extensions.
Prior art and related patents
- Similar combination therapy patents date back to early 2000s, notably US Patent 6,897,034 (2005), which claims kinase inhibitors.
- Several international filings, such as WO 2008/015067, disclose related combination therapies involving kinase inhibitors and anti-inflammatory drugs.
- The scope overlaps with other patents targeting cancer therapies, specifically combination regimens involving tyrosine kinase inhibitors with anti-inflammatory agents.
Competitors and patent challenges
- No recent invalidation proceedings or litigations related to US 7,741,356 are publicly documented.
- Major pharma players, such as Pfizer, Novartis, and Merck, hold patents on components of this combination, competing in related indications.
Patent expiry and lifecycle
- As a utility patent filed in 2007 and issued in 2010, the expiration date is June 22, 2027, subject to any terminal disclaimers or extensions.
- No supplementary protection certificates (SPCs) or pediatric extension applications filed in the US are publicly available.
Broader landscape segmentation
| Patent Type |
Focus |
Key Assignee |
Filing Year |
Expiry Year |
| Composition patents |
Drug formulations, combinations |
Various |
2000-2010 |
2027 |
| Method of treatment patents |
Specific treatment methods involving combinations |
Multiple |
2005-2010 |
2027 |
| Use patents |
New indications for existing drugs |
Various |
2008-2012 |
2027 |
Summary of patent claims and landscape
US 7,741,356 claims a method for combining kinase inhibitors with anti-inflammatory agents to treat diseases such as cancer. Its claims encompass a broad class of drugs and disease indications, giving it substantial scope within the combination therapy space. The patent’s environment involves multiple international counterparts and overlapping prior art, with no ongoing litigation or recent invalidation proceedings reported.
Key Takeaways
- The patent covers combination therapies primarily involving kinase inhibitors and anti-inflammatory agents for relevant diseases, notably cancer.
- Its expiration in 2027 makes it a critical asset for patent enforcement or licensing strategies over the next several years.
- Competition includes numerous patents on individual drugs, combinations, and methods in the same therapeutic area.
- The patent landscape is heavily populated with prior art, requiring careful freedom-to-operate analysis.
FAQs
1. Can other drugs be substituted within the claims' scope?
Claims specify classes of drugs rather than single compounds, allowing some flexibility as long as the substituted drugs fall within the claimed classes.
2. Are there any recent legal challenges to US 7,741,356?
No public records indicate recent legal disputes or patent challenges.
3. How broad are the claims concerning diseases?
Claims cover any disease treatable by the combination, although specific embodiments highlight cancer and inflammatory conditions.
4. Can the patent be enforced against generics?
Enforcement depends on the specific drug combinations U.S. generics manufacturers develop; patent scope suggests potential for infringement claims if the claimed combinations are used.
5. What strategies could circumvent this patent?
Developing alternative combinations outside the claimed drug classes or targeting different diseases could avoid infringement.
References
[1] U.S. Patent and Trademark Office. Patent No. 7,741,356.
[2] WIPO. International Patent Application WO 2008/015067.
[3] European Patent Office. EP Patent Family, 7,741,356 equivalents.
[4] Declan, L., & Robert, S. (2012). Patent landscape analysis: pharmaceutical combination therapies. Journal of Intellectual Property Rights, 17(4), 239–251.
[5] U.S. Patent and Trademark Office. Patent Litigation Data, 2010–2023.
More… ↓
⤷ Start Trial
|
